COVID-19 Project Team: Difference between revisions

Jump to navigation Jump to search
Line 32: Line 32:
* [[User:Aisha Adigun|Aisha Adigun, M.D.]]   
* [[User:Aisha Adigun|Aisha Adigun, M.D.]]   
* [[User:Harmeetkharoud91|Harmeet Kharoud, M.D,. MPH]]
* [[User:Harmeetkharoud91|Harmeet Kharoud, M.D,. MPH]]
*[[User:Sara Haddadi|Sara Haddadi, M.D.]]
* [[User:Agnesrinky|Rinky Agnes Botleroo, M.B.B.S.]]
* [[User:Agnesrinky|Rinky Agnes Botleroo, M.B.B.S.]]
* [[user:Nuha|Nuha AL-Howthi, MD]]
* [[user:Nuha|Nuha AL-Howthi, MD]]

Revision as of 06:04, 21 June 2020

COVID-19 Project
Introduction
Team
Meetings' Summary
Topics
Ongoing Clinical Trials

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]

Meet The Team

Associate Editor(s)-in-Chief:

  • The name of the leaders are written in bold:

Cardiovascular Disorders of COVID-19 Team Members

Dermatologic Disorders of COVID-19 Team Members

Frequently Asked Inpatient Questions Team Members

Frequently Asked Outpatient Questions Team Members

Gastrointestinal disorders and COVID-19

Hematologic disorders of COVID-19 Team Members

Nephrologic Disorders of COVID-19 Team Members

Neurologic Disorders and COVID-19 Team Members

Ongoing Clinical Trials of COVID-19 Team Members

Pediatrics and COVID-19

Pulmonary Disorders and COVID-19 Team Members